VolitionRx

VolitionRx

VolitionRx was founded in 2008 and is headquartered in Henderson, Nevada, with a research and manufacturing arm in Isnes, Belgium. Cameron Reynolds has served as President and CEO since the company's formative years, steering the development of its Nu.Q platform, which uses antibodies to detect fragments of chromosomes called nucleosomes in the blood. The firm has pursued a direct-to-consumer and clinical validation strategy simultaneously, seeking to embed its assays in veterinary oncology, human wellness, and large-scale cancer screening. The company trades on the NYSE American under the ticker VNRX. The company's core technology detects circulating nucleosomes — structures that package DNA — as epigenetic biomarkers for diseases including colorectal cancer, pancreatic cancer, and sepsis. Unlike liquid-biopsy competitors that hunt for rare circulating tumor DNA, VolitionRx's approach measures general nucleosome levels and specific epigenetic modifications with a simple ELISA-based assay. Confirmed product lines include Nu.Q Vet, a canine cancer-screening test, and Nu.Q Discover, a research-use-only tool for human disease. The firm has partnered with university hospitals in Europe and Asia for large-scale validation studies, including a colorectal cancer trial in Denmark and a COVID-19 severity study early in the pandemic (per the firm's official communications, 2020–2023). VolitionRx has historically run a lean operation with fewer than 100 employees, supplementing its internal R&D with grant funding, licensing agreements, and equity raises. It operates a subsidiary, Volition Veterinary, which led the launch of Nu.Q Vet in the United States through an exclusive supply agreement with Heska Corporation, itself acquired by Mars Petcare in 2023. The firm's financials are publicly disclosed through SEC filings, and it has funded development through periodic public offerings rather than large-scale institutional venture rounds. In July 2023, the company announced the appointment of Rodney Gerard as Chief Financial Officer (per the firm, July 2023). The structural differentiator for VolitionRx is its hybrid diagnostic-and-IP licensing model, which divorces it from the pure-play biotech framework. Instead of building a central lab network, the firm designs assays that can be run on standard hospital ELISA instruments already in use worldwide. This capital-light distribution strategy targets commoditized laboratory infrastructure, positioning VolitionRx as a reagent rather than a service business — a distinction with direct consequences for margin structure and commercial scalability.